Skip to content

Monopar Therapeutics Inc.: 10-Q filed 2022-08-11

What Monopar Therapeutics Inc. reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 23 published measures, 68 facts as tagged in accession 0001654954-22-011015.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-11
Fiscal period
fiscal Q2 2022
Accession
0001654954-22-011015 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Monopar Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-3016,737,111USD
At 2021-12-3120,521,614USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-302,220,088USD
At 2021-12-311,580,543USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-3014,517,023USD
At 2022-03-3116,966,911USD
At 2021-12-3118,941,071USD
At 2021-06-3023,353,632USD
At 2021-03-3125,100,268USD
At 2020-12-3115,691,991USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-3016,463,569USD
At 2021-12-3120,303,869USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-2,762,931USD91
2022-01-01 to 2022-06-30-5,219,653USD181
2021-04-01 to 2021-06-30-2,080,169USD91
2021-01-01 to 2021-06-30-3,964,188USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-3,778,275USD181
2021-01-01 to 2021-06-30-3,344,180USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-82,126USD181
2021-01-01 to 2021-06-3010,897,287USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-46,508,036USD
At 2021-12-31-41,288,383USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-06-30857,105USD181
2021-01-01 to 2021-06-30725,825USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-2,763,348USD91
2022-01-01 to 2022-06-30-5,220,534USD181
2021-04-01 to 2021-06-30-2,092,395USD91
2021-01-01 to 2021-06-30-3,987,110USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-3016,652,748USD
At 2021-12-3120,521,614USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-302,186,996USD
At 2021-12-311,580,543USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,763,348USD91
2022-01-01 to 2022-06-305,220,534USD181
2021-04-01 to 2021-06-302,092,395USD91
2021-01-01 to 2021-06-303,987,110USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,078,471USD91
2022-01-01 to 2022-06-303,756,403USD181
2021-04-01 to 2021-06-301,476,430USD91
2021-01-01 to 2021-06-302,683,209USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-3012,700,737shares
At 2021-12-3112,598,125shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2022-06-3016,463,569USD
At 2021-12-3120,303,869USD
At 2021-06-3024,292,850USD
At 2020-12-3116,737,109USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-3060,994,892USD
At 2021-12-3160,220,016USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2022-06-3017,466USD
At 2021-12-31-3,160USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-06-3084,363USD
At 2021-12-310USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-06-3080,125USD
At 2021-06-300USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-2,762,931USD91
2022-01-01 to 2022-06-30-5,219,653USD181
2022-01-01 to 2022-03-31-2,456,722USD90
2021-04-01 to 2021-06-30-2,080,169USD91
2021-01-01 to 2021-06-30-3,964,188USD181
2021-01-01 to 2021-03-31-1,884,019USD90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-2,741,721USD91
2022-01-01 to 2022-06-30-5,199,027USD181
2021-04-01 to 2021-06-30-2,080,224USD91
2021-01-01 to 2021-06-30-3,961,471USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30684,877USD91
2022-01-01 to 2022-06-301,464,131USD181
2021-04-01 to 2021-06-30615,965USD91
2021-01-01 to 2021-06-301,303,901USD181

Inspect the source

Entity
Monopar Therapeutics Inc. / CIK 0001645469
Captured
2026-09-21T17:22:36.466Z
SEC response SHA-256
11b3f240217511123d89b32408ab3beb4dce0c8844d2a4f4fb7c1085084888d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001645469.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))